CHSU Discovery

Background

Ischemic colitis is the most common presentation of mesenteric ischemia and is associated with significant morbidity and mortality. Coagulopathy has been associated with the development of ischemic colitis. Coronavirus disease 2019 (COVID-19) infection can lead to a variety of pathology and physiological derangements, including coagulopathy. Some case reports have described severe ischemic colitis in patients with COVID-19 infection. Our study aimed to elucidate the impact of COVID-19 infection on ischemic colitis outcomes.

Methods

Patients with a diagnosis of ischemic colitis were identified using the 2020 Nationwide Inpatient Sample (NIS). Patients were stratified based on the presence of COVID-19 infection. Data were collected regarding mortality, shock, blood transfusion, length of stay, hospital charges, age, gender, race, primary insurance, median income, hospital region, hospital bed size, and comorbidities. The relationship between COVID-19 and outcomes was analyzed using multivariate regression analysis.

Results

A total of 67,685 patients were included in the final analysis. COVID-19 was associated with an increased risk of in-hospital mortality (adjusted odds ratio (aOR): 4.006, P < 0.001), shock (aOR: 1.62, P = 0.002), and blood transfusion (aOR: 1.49, P = 0.007). COVID-19 was also associated with an increased length of stay (16.2 days vs. 8.7 days) and higher total hospital charges ($268,884.1 vs. $145,805.9).

Conclusions

Among hospitalized patients with ischemic colitis, COVID-19 infection was associated with worse outcomes and higher resource utilization. Further studies are needed to investigate the mechanisms underlying this association.